#ESHAL2022 - MEET THE EXPERT SESSIONS REGISTRATION OPEN!

ESH 3rd How to Diagnose and Treat

ACUTE LEUKAEMIAS

March 10-13, 2022

E-CONFERENCE

#ESHAL2022

---

REGISTRATION IS NOW OPEN
FOR THE MEET THE EXPERT SESSIONS

SEATS ARE LIMITED
AND PRE-REGISTRATION IS REQUIRED

DO NOT MISS THE OPPORTUNITY!

---

About the Meet the Expert sessions:

The ESH 3rd How to Diagnose and Treat ACUTE LEUKAEMIAS Meet the Expert sessions are live, interactive sessions that offer you an opportunity for informal dialogue with world authorities. The number of seats available is strictly limited, first come-first serve*. The sessions will not be recorded.

There will be no formal presentation. The Session Leaders are present to answer your questions and to provide you with expert guidance.

Registration Fee: 20 euros

*These sessions are open to registered academic biologists and clinicians only.

---

Meet the Expert sessions programme

---

REGISTRATION IS OPEN AND OFFERED FOR FREE
as a gesture of solidarity during these difficult times.

---

About the E-Conference:

In view of continuing COVID-19 related challenges and uncertainties, the ESH 3rd How to Diagnose and Treat Acute Leukaemias conference will be held as a VIRTUAL EVENT.

ESH How to Diagnose and Treat meetings are disease-specific meetings that address state-of-the-art diagnostic and clinical management which is greatly facilitated by and discussion of real clinical cases. An important incentive will be to promote interaction between the speakers and participants.

Novel and still evolving insights into the biology and diagnosis of acute leukaemias, including acute myeloid leukaemias (AMLs) and acute lymphoblastic leukaemias (ALL), has resulted in new drug approvals and new therapeutic options to treat newly-diagnosed as well as relapsed/refractory disease.

The programme of this “3rd How to Diagnose and Treat: Acute Leukaemias” meeting will integrate of genomic analysis and cutting-edge technics in routine diagnosis, gene mutation-directed therapies and new standard treatment algorithms, allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes.

---

CONFERENCE MAIN TOPICS:

• Diagnosis and rare diseases
• Measurable Residual Disease (MRD)
• Leukaemia treatment dilemmas
• Intensive chemotherapy for older fit patients
• MRD level before transplant
• Leukaemia treatment challenges
• Ph-positive ALL
• CAR-T cell for ALL patients
• Immune therapies to treat leukaemia patients
• Haematopoietic stem cell transplantation

---